BioAtla reports 36% ORR in NSCLC and meets Go criteria in multiple sarcoma subtypes for BA3011

BioAtla, Inc.

NSCLC Phase 2 Part 1: ORR 36% (5/14), 42% in non-squamous (5/12); 1 CR and 4 PRs.
Sarcoma: Go criteria met for UPS, osteosarcoma, liposarcoma, and synovial sarcoma into Part 2.
UPS (Phase 1&2, n=10): ORR 50% (4/8 evaluable), 3-month PFS rate 50%, median PFS 6.8 months.
Osteosarcoma (n=6): 3-month PFS rate 66.7%; liposarcoma (n=6): 66.7%; synovial sarcoma (n=5): 54%.
FDA supportive of proposed registrational Part 2 study in UPS (n=80, primary endpoint ORR); enrollment expected by year-end 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.